Likewise the strategies that provide for successive or combined injection of CD19- and BCMA-specific CAR products have been emerging, especially to patients after deep tumor reduction in BCMA-targeted therapy, where resistant CD19-positive clones survive [193,194,195]. The gene discussed is CD19; the disease is neoplasm.